arrow
G

Giuseppe Gritti

roche pharma ag
H指数:27
被引数:3,206

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial

Englumafusp alfa联合glofitamab治疗b 细胞非霍奇金淋巴瘤: 1期试验

2026-07-160
OAAI
Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series

体外细胞因子血吸附治疗B细胞恶性肿瘤T细胞免疫治疗继发性严重糖皮质激素难治性细胞因子释放综合征:一个病例系列

2026-06-220
OA
Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

更正: Brentuximab vedotin联合化疗治疗一线系统性间变性大细胞淋巴瘤: 5年随访时ECHELON-2研究的亚组分析

2026-01-280
OAAI
CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation study

CD19-CD28共刺激双特异性抗体联合glofitamab在复发/难治性B-NHL中的I期剂量递增研究

2026-01-010
OAAI
Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma

PET4反应与ECHELON-2试验中CD30+外周T细胞淋巴瘤患者接受BV-CHP vs CHOP治疗的结局相关性研究

2025-08-210
OAAI
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

brentuximab vedotin联合化疗用于一线系统性间变性大细胞淋巴瘤的治疗:ECHELON-2研究5年随访的亚组分析

2025-08-010
OAAI
Preclinical development of anti-CD21 chimeric antigen receptor T cells to treat T cell acute lymphoblastic leukemia

抗CD21嵌合抗原受体T细胞治疗T细胞急性淋巴细胞白血病的临床前开发

2025-04-160
PRE
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation

供者来源的经 Sleeping Beauty 转座子工程改造的 CARCIK-CD19 细胞在急性淋巴细胞白血病异基因移植后复发。

2025-04-030
OA
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

杜韦利司在复发/难治性外周T细胞淋巴瘤患者中的疗效:PRIMO试验2期最终结果

BLOOD
IF23.1
2024-11-051
PRE
Rapid immune reconstitution following the infusion of autologous, Blinatumomab Expanded T-cells (BET) in patients with B-cell indolent NHL or CLL
2024-04-260
OAAI
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
2023-08-114
OAAI
Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study
2023-01-1715
OAAI
Human inhalable antibody fragments neutralizing SARS-CoV-2 variants for COVID-19 therapy
2022-05-0116
OAAI